Skip to main content

GT Biopharma, Inc.

GTBP
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0000109657

No open-market purchases or sales by GT Biopharma, Inc. insiders were filed in the last 90 days; 59 institutions reported holding it in 13F filings for Q2 2026, worth $1.02M in total; no superinvestor holds it.

Q3 2021 vs. Q2 2021

How the institutions holding GT Biopharma, Inc. changed between Q2 2021 and Q3 2021.

All holders in Q3 2021All holders in Q2 2021

13F holders of GTBP: Q2 2021 compared with Q3 2021
MeasureQ2 2021Q3 2021Change
Holders5054+4
Shares4.51M4.76M+246.4K (+5.5%)
Value$69.9M$32.1M−$37.8M (−54.0%)

New holders (14)

Institutions that held GT Biopharma, Inc. at the end of Q3 2021 but not at the end of Q2 2021.

Institutions new to GTBP in Q3 2021
InstitutionSharesValue% of portfolio
Two Sigma Investments, LP162,823$1.10M0.00%
Renaissance Technologies LLC84,700$571.0K0.00%
Goldman Sachs Group Inc52,426$353.0K0.00%
Susquehanna International Group, LLP46,279$312.0K0.00%
Millennium Management LLC34,127$230.0K0.00%
Cubist Systematic Strategies, LLC33,703$227.0K0.00%
Franklin Resources Inc28,500$192.0K0.00%
ExodusPoint Capital Management, LP22,200$150.0K0.00%
State Board of Administration of Florida Retirement System18,224$123.0K0.00%
AQR Capital Management LLC16,975$114.0K0.00%
Susquehanna Fundamental Investments, LLC14,260$96.0K0.00%
Qube Research & Technologies Ltd14,315$96.0K0.00%
Welch Group, LLC10,000$67.0K0.00%
Russell Investments Group, Ltd.9,642$64.0K0.00%

Sold out (10)

Institutions that held GT Biopharma, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.